Latest Intelligence on Therapy Area in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Genentech/Roche: significant potential for Avastin in glioma

Clinical phase II trial data has shown a combination of Genentech/Roche's Avastin and Pfizer's Camptosar to confer antitumor activity in the treatment of glioma. Although Avastin has already reached blockbuster status in other indications, the severe unmet needs and lack of alternative treatment options in this patient population mean that, if approved, eventual uptake is likely to be promising.

Published By Datamonitor
19 Feb 2007
CommentWire
CommentWire

Genentech: Avastin may drive it into pole position

Positive trial data for Avastin drove Genentech's [DNA] share price up by almost 25% and parent company Roche's [ROCZ.S] share price by over 5%. Roche and Genentech have partnered to form the largest global player for cancer drugs, and Avastin looks set to provide them with another superstar product. Genentech's future as a major biotech player in the cancer market thus seems assured.

Published By Datamonitor
16 Mar 2005
CommentWire
CommentWire

Genentech: Avastin on track for 2004 launch

Genentech looks set to add Avastin to its growing number of successfully marketed innovative products, judging by the announcement of positive phase III clinical trial results in colorectal cancer patients. The results pave the way for Avastin to be launched in late 2004, making it the first angiogenesis inhibitor available for the treatment of colorectal cancer.

Published By Datamonitor
20 May 2003
CommentWire
CommentWire

Genentech: rejects Roche bid

Genentech has declined the $43.7 billion takeover bid made by Swiss pharmaceutical giant Roche, on the grounds that the offer undervalues the benefits that full-ownership of the US biotech would provide. Genentech's unsurprising decision leaves the door open to further negotiations, with a deal expected to be finalized within the next few months.

Published By Datamonitor
14 Aug 2008
CommentWire
CommentWire

Hepatitis A vaccine: more protection than expected

A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Imclone/Merck KGaA: first approval for Erbitux

The Swiss agency for therapeutic products has approved Erbitux for the treatment of patients with colorectal cancer who no longer respond to standard chemotherapy treatment with irinotecan. This is likely to be followed by approval across Europe, where it should provide Merck KGaA [MRK.F] with annual sales of more than $260 million by 2008.

Published By Datamonitor
04 Dec 2003
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
CommentWire
CommentWire

Merck KGaA: good news finally for Erbitux

Swiss regulators have recommended the approval of Merck KGaA's [MRK.F] Erbitux as a second-line therapy for colorectal cancer. The drug is set to be approved within 30 days and Switzerland will be the first market to approve the drug. Given Erbitux's past difficulties, it is welcome news, not only for Merck, but also for ImClone [IMCL] and BMS [BMY].

Published By Datamonitor
17 Nov 2003
Expert View
Expert View

Novartis eyes Alcon to drive diversification strategy

Novartis has agreed to acquire a controlling stake in ophthalmology specialist Alcon for around $39 billion, revealing a clear intention to drive diversification from its core prescription pharmaceutical business. Although Alcon will not come cheap, the acquisition represents a positive, long-term strategy by Novartis which faces intensifying generic competition over the next five years.

Published By Datamonitor
08 Apr 2008
Expert View
Expert View

Novartis's novel bronchodilator paves way for potent COPD combinations

Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).

Published By Datamonitor
09 Jun 2005

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

No help is available.